Vericiguat treatment of heart failure: A systematic review and meta-analysis

doi:10.12998/wjcc.v11.i35.8330

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 35

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7530)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-10) series, Tables (1-1) series.

Item

Count

PDF

167

WORD

HTML

3361

Figures (1-10)

462

Tables (1-1)

476

Sum=4483

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

270

Download

1107

Sum=1377

Publishing Process of This Article

Item

Count

Browse

232

Download

1189

Sum=1421

Dec 16, 2023 (publication date) through Feb 20, 2026

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Clin Cases. Dec 16, 2023; 11(35): 8330-8342
Published online Dec 16, 2023. doi: 10.12998/wjcc.v11.i35.8330

Vericiguat treatment of heart failure: A systematic review and meta-analysis

Heng Yang, Chao Luo, Wan-Qi Lan, Yan-Hua Tang

Heng Yang, Chao Luo, Wan-Qi Lan, Yan-Hua Tang, Department of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330008, Jiangxi Province, China

Co-first authors: Heng Yang and Chao Luo.

Author contributions: Yang H, Luo C, and Lan WQ contributed to data collection and analysis; Yang H and Luo C drafted the manuscript; Tang YH reviewed and revised the manuscript. All authors read and approved the final version of this manuscript.

Supported by Key Research and Development projects in Jiangxi Province, No. 20223BBG71010; and National Natural Science Foundation of China, No. 81960058.

Conflict-of-interest statement: All the authors declare that they have no conflict of interest.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Corresponding author: Yan-Hua Tang, PhD, Professor, Department of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Donghu District, Nanchang 330008, Jiangxi Province, China. tyh6565@163.com

Received: September 13, 2023
Peer-review started: September 13, 2023
First decision: November 1, 2023
Revised: November 12, 2023
Accepted: November 28, 2023
Article in press: November 28, 2023
Published online: December 16, 2023
Processing time: 91 Days and 11.5 Hours

ARTICLE HIGHLIGHTS

Research background

Heart failure (HF) causes a substantial socioeconomic burden, and there is an urgent need for effective treatment.

Research motivation

Vericiguat may be an effective therapeutic agent for HF. This study aims to investigate the benefits of Vericiguat in patients with chronic heart failure (CHF).

Research objectives

To assess the efficacy and safety of Vericiguat in the treatment of CHF.

Research methods

We searched for randomized controlled trials of Vericiguat for the treatment of CHF and performed meta-analyses using Revman 5.4 and the Cochrane Handbook.

Research results

A total of 5919 patients were enrolled in this study. The results showed that Vericiguat treatment reduced the composite endpoints of cardiovascular mortality and first HF-related hospitalization [RR = 0.91, 95%CI: (0.85, 0.98), P = 0.01] and the risk of HF-related hospitalizations [RR = 0.92, 95%CI: (0.84, 1.00), P = 0.05] in patients with CHF. Vericiguat did not increase the risk of adverse reactions and serious adverse events.

Research conclusions

Vericiguat is effective and safe in treating heart failure patients with reduced ejection fraction.

Research perspectives

Current therapeutic measures for CHF are improving, but patients still have a dismal prognosis. As a novel therapeutic agent for heart failure, Vericiguat may help to slow down the progression of heart failure and promote patient recovery.